Skip to main content

Table 3 Unadjusted direct mean annual asthma-related mean costs by category of service and severity

From: Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis

Service a

Total

n = 20,410

Mild intermittent n = 14,191

Mild Persistent n = 3680

Moderate Persistent n = 1408

Severe persistent n = 1131

p-value b

Medical services c

 ED visits

$6 (39.3)

$21 (57)

$26 (78)

$20 (87)

0.187

 Hospitalizations

$105 (946)

$239 (1492)

$368 (1838)

$662 (2027)

0.000

 Specialized physician visits

$20 (47)

$15 (35)

$23 (52)

$38 (66)

$58 (91)

0.000

 General physician visits

$37 (61)

$30 (39)

$41 (59)

$54 (77)

$100 (158)

0.000

 Other ambulatory services

$7 (68)

$5 (61)

$9 (85)

$10 (49)

$22 (99)

0.000

 Any medical service d

$178 (958)

$51 (76)

$335 (1489)

$498 (1840)

$865 (2050)

0.000

Asthma medication prescriptions c

 Controller medications

  ICS

$20 (124)

$5 (52)

$28 (117)

$84 (269)

$101 (306)

0.000

  ICS + LABA

$24 (211)

$0.7 (19)

$12 (115)

$147 (513)

$208 (606)

0.000

  LABA

$0.5 (16)

$0 (2)

$0.7 (14)

$0.8 (11)

$5 (62)

0.000

  LM

$12 (89)

$0 (0)

$10 (61)

$37 (143)

$137 (296)

0.000

 Rescue Medications

  Oral corticosteroids

$14 (74)

$0.3 (7)

$15 (36)

$48 (100)

$138 (249)

0.000

  SABA

$25 (127)

$3 (27)

$38 (114)

$98 (231)

$166 (375)

0.000

  Any medication e

$152 (780)

$16 (108)

$147 (320)

$563 (895)

$1370 (2755)

0.000

Total mean costs f

$331 (1278)

$67 (134)

$482 (1506)

$1061 (1983)

$2235 (3426)

0.000

  1. a Mean values and their (SD) are reported and were calculated using the total number of subjects in each column as denominator
  2. b Welch analysis of variance-ANOVA test
  3. c One patient may contribute to the costs of different medical services or prescriptions
  4. d, e, f Mean values represent the sum of costs derived from all medical services d, medications e (or both f ) presented during the cost-analysis period and divided by the total number of subjects in each disease category.
  5. ED emergency department; ICS inhaled corticosteroids; ICS+LABA inhaled corticosteroids-long acting B2 agonist combination; LABA long acting B2 agonist; LM leukotriene modifiers; SABA short acting B2 agonist